• What Is ‘Chemo Brain’?

    The National Cancer Institute’s Todd Horowitz discusses cancer-related cognitive impairment.

    by Anna Azvolinsky

  • From the Editor-in-Chief

    Synthetic Lethality and Cancer: Aiming an Arrow at Achilles’ Heel

    Insights about synthetic lethality have been used to develop cancer treatments.

    by William G. Nelson, MD, PhD

  • Recognizing AI’s Potential

    Pathologists and radiologists are leading the way in the use of artificial intelligence (AI) to find and track cancer. Machine learning could lay the foundation for using AI more broadly to advance cancer diagnosis and choice of treatment.

    by Stephen Ornes

  • Forward Look

    From Cold Virus to Cancer Fighter

    Neurosurgeon Frederick F. Lang discusses virus-powered cancer treatments.

    by Sue Rochman

  • Forward Look

    Opening Clinical Trials to HIV-Positive Cancer Patients

    Including patients with HIV is part of a larger effort to broaden cancer clinical trial eligibility.

    by Andy Kopsa

  • Pushing the Immune System to Its Limits

    Immunotherapy drugs have led to long-lasting remissions for some cancer patients with advanced disease. They also come with a new and diverse array of side effects.

    by Kate Yandell

  • What Older Patients Value

    Many older adults with cancer place more importance on maintaining their independence and cognitive abilities than on living as long as possible.

    by Cheryl Platzman Weinstock

  • Omitting Obesity

    Many cancer clinical trials do not track what proportion of enrolled patients are obese, a study finds. These patients may be underrepresented in research.

    by Cici Zhang

  • Measuring Your Movement

    Researchers are exploring whether wearable personal activity monitors could provide doctors with a more complete picture of cancer patients’ well-being.

    by Brad Jones

  • The Ins and Outs of Tumor Testing

    In a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates.

    by Kate Yandell


From the AACR



​Editor-in-Chief William G. Nelson Discusses Cancer Today​


social media

donate to the AACR